Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Here are the latest quarterly results of AJANTA PHARMA. For more details, see the AJANTA PHARMA financial fact sheet and AJANTA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Mar-17* |
3
Jun-17* |
3
Sep-17* |
3
Dec-17* |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 4,768 | 4,731 | 5,404 | 5,871 | 5,303 | 5,110 | 5,441 | 4,851 | |
Other income | Rs m | 24 | 48 | 92 | 152 | 52 | 81 | 152 | 44 | |
Turnover | Rs m | 4,792 | 4,779 | 5,496 | 6,022 | 5,356 | 5,191 | 5,594 | 4,895 | |
Expenses | Rs m | 3,154 | 3,457 | 3,567 | 3,896 | 3,908 | 3,535 | 3,779 | 3,778 | |
Gross profit | Rs m | 1,614 | 1,275 | 1,837 | 1,975 | 1,395 | 1,575 | 1,662 | 1,073 | |
Depreciation | Rs m | 189 | 134 | 146 | 150 | 166 | 172 | 175 | 187 | |
Interest | Rs m | 9 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | |
Profit before tax | Rs m | 1,440 | 1,187 | 1,783 | 1,975 | 1,280 | 1,483 | 1,638 | 930 | |
Tax | Rs m | 300 | 239 | 464 | 501 | 335 | 425 | 385 | 261 | |
Profit after tax | Rs m | 1,140 | 948 | 1,319 | 1,475 | 945 | 1,058 | 1,254 | 669 | |
Gross profit margin | % | 33.8 | 26.9 | 34.0 | 33.6 | 26.3 | 30.8 | 30.5 | 22.1 | |
Effective tax rate | % | 20.8 | 20.2 | 26.0 | 25.3 | 26.2 | 28.7 | 23.5 | 28.0 | |
Net profit margin | % | 23.9 | 20.0 | 24.4 | 25.1 | 17.8 | 20.7 | 23.0 | 13.8 | |
Diluted EPS | Rs | 13.0 | 10.8 | 15.0 | 16.8 | 10.7 | 12.0 | 14.3 | 7.6 | |
Diluted EPS (TTM) | Rs | 57.6 | 54.8 | 55.0 | 55.5 | 53.3 | 54.5 | 53.8 | 44.6 | |
![]() |
Read: AJANTA PHARMA 3QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: AUROBINDO PHARMA ALEMBIC PHARMA SUN PHARMA DIVIS LABORATORIES ALKEM LABORATORIES
Compare AJANTA PHARMA With: AUROBINDO PHARMA ALEMBIC PHARMA SUN PHARMA DIVIS LABORATORIES ALKEM LABORATORIES
Compare AJANTA PHARMA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
| |
On Friday, share markets in India traded on a negative note throughout the day and ended marginally lower after a volatile day of trading.
For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Should you subscribe to the IPO of Shalby Ltd?
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsManagements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
The real estate sector is ready to make a comeback. This is the stock to consider buying.
A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.
This is the trick to following super investors and not losing money.
Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
More
| |